Spectral AI Inc

Spectral AI Inc(MDAI)股票分析

$1.495

+0.125 (+8.33%)收盘时

Loading chart…
最高
1.530
开盘
1.410
成交量加权均价
1.47
成交量
166.46K
市值
31.47M
最低
1.400
成交额
245.53K
企业价值/息税折旧摊销前利润(TTM)
-1.19

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.

AI 分析 of Spectral AI Inc (MDAI)

买入

Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.

估值指标

Spectral AI Inc(MDAI)当前预期市盈率为 52.36,5 年平均预期市盈率为 6.80。

预期市盈率

严重高估
5 年均值 P/E
6.80
当前P/E
52.36
高估
25.58
低估
-11.98

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-18.84
当前EV/EBITDA
-1.19
高估
3.75
低估
-41.44

预期市销率

合理
5 年均值 P/S
4.76
当前P/S
1.37
高估
9.54
低估
-0.02

Alphio AI 对 MDAI 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MDAI

$2.22

情景价格

基

基准

基准 · 50%MDAI

$2.20

情景价格

悲

悲观

悲观 · 25%MDAI

$1.52

情景价格

事件时间线

2026-10-06 (ET)

09:00:00

Spectral AI Submits NTAP Application to CMS

2026-10-01 (ET)

09:00:00

Spectral AI Completes First Site Initiation Visit for Clinical Study

2026-07-08 (ET)

09:30:00

Spectral AI Appoints Darcy Bajko as Chief Commercial Officer

2026-05-26 (ET)

07:10:00

Spectral AI's DeepView System Receives FDA De Novo Classification

2026-04-08 (ET)

08:50:00

Spectral AI Appoints David McGuire as CFO

资讯

MDAI 常见问题 —— 由 Alphio AI 解答

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易